Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 23
Phase 31
Phase 41

Trial Status

Other5

Role Distribution

Principal Investigator5
PI Rate100%

Activity Timeline

Research Network

Collaboration Network

28 collaborators·51 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

University of Campania Luigi Vanvitelli

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Sandro Pignata, M.D., Ph.D.

National Cancer Institute, Naples

Moderately Similar
9 trials

Shared therapeutic areas:

Ovary CancerEndometrial CarcinomaRecurrent Ovarian Cancer

Worked with same sponsors:

Mario Negri Institute for Pharmacological ResearchNational Cancer Institute, Naples
Collaborated on 4 trials
Similarity Score46%

Francesco Perrone, M.D., Ph.D.

National Cancer Institute, Naples

Moderately Similar
13 trials

Shared therapeutic areas:

Ovary CancerEndometrial CarcinomaRecurrent Ovarian Cancer

Worked with same sponsors:

Mario Negri Institute for Pharmacological ResearchNational Cancer Institute, Naples
Collaborated on 4 trials
Similarity Score46%

Gennaro Daniele, M.D., Ph.D.

National Cancer Institute, Naples

Moderately Similar
4 trials

Shared therapeutic areas:

Ovary CancerEndometrial CarcinomaRecurrent Ovarian Cancer

Worked with same sponsors:

Mario Negri Institute for Pharmacological ResearchNational Cancer Institute, Naples
Collaborated on 4 trials
Similarity Score46%

Nicoletta Colombo, M.D.

European Institute of Oncology

Moderately Similar
3 trials

Shared therapeutic areas:

Ovary CancerRecurrent Ovarian Cancer

Worked with same sponsors:

Mario Negri Institute for Pharmacological ResearchNational Cancer Institute, Naples
Collaborated on 3 trials
Similarity Score32%

Michael B Gill

Power Life Sciences Inc.

Moderately Similar
105 trials

Shared therapeutic areas:

Breast CancerEndometrial CarcinomaOvary Cancer+1 more
Similarity Score30%

Irene Floriani, Ph.D.

Mario Negri Institute

Related
2 trials

Shared therapeutic areas:

Ovary CancerRecurrent Ovarian Cancer

Worked with same sponsors:

Mario Negri Institute for Pharmacological ResearchNational Cancer Institute, Naples
Collaborated on 2 trials
Similarity Score28%

Roldano Fossati, M.D.

Mario Negri Institute

Related
2 trials

Shared therapeutic areas:

Ovary CancerRecurrent Ovarian Cancer

Worked with same sponsors:

Mario Negri Institute for Pharmacological ResearchNational Cancer Institute, Naples
Collaborated on 2 trials
Similarity Score28%

Lei Li, M.D.

Peking Union Medical College Hospital

Related
46 trials

Shared therapeutic areas:

Endometrial CarcinomaOvary CancerRecurrent Ovarian Cancer
Similarity Score23%

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

Related
32 trials

Shared therapeutic areas:

Breast CancerOvary Cancer
Similarity Score15%

John D. Hainsworth, MD

SCRI Development Innovations, LLC

Related
26 trials

Shared therapeutic areas:

Breast CancerOvary Cancer
Similarity Score15%

Publications (0)

No publications found for this investigator.

Clinical Trials (5)

Showing 5 of 5 trials

NCT03410784Phase 2PrincipalInvestigator

Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Ovarian Cancer
Unknown
NCT03503786Phase 2PrincipalInvestigator

Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer

Endometrial Cancer
Unknown
NCT01005641Phase 2PrincipalInvestigator

ELBA: Exemestane and Lapatinib in Advanced Breast Cancer

Breast Cancer
Withdrawn
NCT01706120Phase 4PrincipalInvestigator

Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab

Ovarian Cancer
Unknown
NCT01802749Phase 3PrincipalInvestigator

Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer

Recurrent Ovarian Cancer
Unknown

All 5 trials loaded